Stephen B. Larsen 1, Christian M. Junghanss 1, Angela, Bo Hye Kim 2, Patrick B. Schnell 1
Abstract
This case report serves as an investigation of the relationship between Chronic Fatigue Syndrome (CFS) and ALK-Positive Anaplastic Large Cell Lymphoma (ALCL). Background of CFS: ALCL was considered to be a malignant neoplasm of activated, lacrimal, or natural killer lymphocytes. Symptoms of ALCL also involve chronic fatigue, possibly from the growth of cytokines or involvement of chest and pericardium. As the associations of CFS and cancer have not been fairly addressed, clinicians and investigators can work to increase scientists' and researchers' understanding of the association between CFS and malignancy by encouraging and researching further case stories on this subject. Chronic Fatigue Syndrome (CFS) withdrew from the U.S. Centers for Disease Control and Avoidance diagnostic criteria for myalgic encephalomyelitis (M.E.) due to lysis and its congeners to arise near 6 months. Affective disorders, along with post-traumatic tension, and many general physician practices used in latest American healthcare situations CFS, which includes chronic fatigue, frequency of feeling tired, is largely misdiagnosed as ailment due to frequency of garden-variety reactions. Theoretically, malignancy may be a cause of durable malaise. However, the steer bushings are few, encompass a large range of relationships, and refer to large populations. Anaplastic large cell kinase (ALK) colorectal carcinoma and lesion necrosis factor (TNF) gaitrisma of giant viruses such as measles, rubella, and mumps are potential. ALK is a constitutive cytokine receptor-activated deposit of two alleles in humans. We can report on an association between chronic fatigue and a case of Anaplastic Large Cell Lymphoma.
Keywords: ALK; NHL; Cervical Lymphadenopathy
Copyright © 2020 by Schnell et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Chang CM, Warren JL, Engels EA. Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults. Cancer 2012;118(23):5929-36. [PubMed] 2. Fluge Ø, Risa K, Lunde S, et al. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. PLoS One 2015;10(7):e0129898. [PubMed] 3. Savage KJ, Harris NL, Vose JM, et al. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111(12):5496-504. [PubMed] 4. Varghese GM, Trowbridge P, Doherty T. Investigating and managing pyrexia of unknown origin in adults. BMJ 2010;341:C5470. [PubMed] 5. Srikantharajah M, Mahendra P, Vydianath B, et al. Kikuchi-Fujimoto disease: a rare but important differential diagnosis for lymphadenopathy. BMJ Case Rep 2014;2014. [PubMed] 6. Zeller B, Loge JH, Kanellopoulos A, et al. Chronic fatigue in long-term survivors of childhood lymphomas and leukemia: persistence and associated clinical factors. J Pediatr Hematol Oncol 2014;36(6):438-44. [PubMed] 7. Levine PH, Peterson D, McNamee FL, et al. Does chronic fatigue syndrome predispose to non-Hodgkin's lymphoma? Cancer Res 1992;52(19 Suppl):5516s-5518s. [PubMed] 8. Grufferman, S, Eby NL, Huang M, et al. Epidemiologie investigations of an outbreak of chronic fatigue immune dysfunction syndrome in a defined population. Am. J. Epidemici 1988;12ft:898. 9. Bradley AS, Ford B, Bansal AS. Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. Clin Exp Immunol 2013;172(1):73-80. [PubMed] 10. Dearden CE, Johnson R, Pettengell R, et al. British Committee for Standards in Haematology. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 201;153(4):451-85. [PubMed] 11. Hsu C, Woodgett J, Huang TH, et al. CIP2A overexpression up-regulates Akt signaling pathway in metastasis breast cancer cell. American Journal of BioMedicine 2015;3(10):658-673. [Abstract/Full-Text] READ THE FULL ARTICLE For any technique error please contact us and will be response to sending purchase article by email. Thank you for visiting American Journal of BioMedicine. * = Required fields [gravityform id="6" name="Feedback"]
References
